These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 9587367)
1. [TSG101 and breast cancer: a correctly named tumor-suppressor gene?]. Bénard J; Ahomadégbé JC Bull Cancer; 1997 Dec; 84(12):1141-2. PubMed ID: 9587367 [TBL] [Abstract][Full Text] [Related]
2. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528 [TBL] [Abstract][Full Text] [Related]
3. Identification of cellular TSG101 protein in multiple human breast cancer cell lines. Zhong Q; Chen CF; Chen Y; Chen PL; Lee WH Cancer Res; 1997 Oct; 57(19):4225-8. PubMed ID: 9331081 [TBL] [Abstract][Full Text] [Related]
4. Absence of TSG101 transcript abnormalities in human cancers. Trink B; Pai SI; Spunt SL; Raman V; Cairns P; Jen J; Gabrielson E; Sukumar S; Sidransky D Oncogene; 1998 May; 16(21):2815-8. PubMed ID: 9652749 [TBL] [Abstract][Full Text] [Related]
5. Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers. Turpin E; Dalle B; de Roquancourt A; Plassa LF; Marty M; Janin A; Beuzard Y; de Thé H Oncogene; 1999 Dec; 18(54):7834-7. PubMed ID: 10618725 [TBL] [Abstract][Full Text] [Related]
6. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues. Willeke F; Ridder R; Bork P; Klaes R; Mechtersheimer G; Schwarzbach M; Zimmer D; Kloor M; Lehnert T; Herfarth C; von Knebel Doeberitz M Mol Carcinog; 1998 Dec; 23(4):195-200. PubMed ID: 9869447 [TBL] [Abstract][Full Text] [Related]
7. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Steiner P; Barnes DM; Harris WH; Weinberg RA Nat Genet; 1997 Aug; 16(4):332-3. PubMed ID: 9241265 [No Abstract] [Full Text] [Related]
8. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824 [TBL] [Abstract][Full Text] [Related]
9. Role of TSG101 in uterine cervix cancer. O'Boyle JD; Proctor ML; Fong KM; Lin WM; Miller DS; Muller CY Gynecol Oncol; 1999 Dec; 75(3):401-5. PubMed ID: 10600297 [TBL] [Abstract][Full Text] [Related]
10. Truncated TSG101 transcripts in human leukemia and lymphoma cell lines. Hosokawa Y; Nagai E; Seto M J Cancer Res Clin Oncol; 2000 Feb; 126(2):79-84. PubMed ID: 10664246 [TBL] [Abstract][Full Text] [Related]
11. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880 [TBL] [Abstract][Full Text] [Related]
12. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Li L; Li X; Francke U; Cohen SN Cell; 1997 Jan; 88(1):143-54. PubMed ID: 9019400 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Liu RT; Huang CC; You HL; Chou FF; Hu CC; Chao FP; Chen CM; Cheng JT Oncogene; 2002 Jul; 21(31):4830-7. PubMed ID: 12101421 [TBL] [Abstract][Full Text] [Related]
14. Defining a common region of deletion at 13q21 in human cancers. Chen C; Brabham WW; Stultz BG; Frierson HF; Barrett JC; Sawyers CL; Isaacs JT; Dong JT Genes Chromosomes Cancer; 2001 Aug; 31(4):333-44. PubMed ID: 11433524 [TBL] [Abstract][Full Text] [Related]
15. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oh KB; Stanton MJ; West WW; Todd GL; Wagner KU Oncogene; 2007 Aug; 26(40):5950-9. PubMed ID: 17369844 [TBL] [Abstract][Full Text] [Related]
16. Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers. Wang Q; Driouch K; Courtois S; Champème MH; Bièche I; Treilleux I; Briffod M; Rimokh R; Magaud JP; Curmi P; Lidereau R; Puisieux A Oncogene; 1998 Feb; 16(5):677-9. PubMed ID: 9482115 [TBL] [Abstract][Full Text] [Related]
17. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Filippova GN; Lindblom A; Meincke LJ; Klenova EM; Neiman PE; Collins SJ; Doggett NA; Lobanenkov VV Genes Chromosomes Cancer; 1998 May; 22(1):26-36. PubMed ID: 9591631 [TBL] [Abstract][Full Text] [Related]
18. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. Carney ME; Maxwell GL; Lancaster JM; Gumbs C; Marks J; Berchuck A; Futreal PA J Soc Gynecol Investig; 1998; 5(5):281-5. PubMed ID: 9773405 [TBL] [Abstract][Full Text] [Related]
19. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Lerman MI; Minna JD Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536 [TBL] [Abstract][Full Text] [Related]
20. Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers. Chang JG; Su TH; Wei HJ; Wang JC; Chen YJ; Chang CP; Jeng CJ Br J Cancer; 1999 Feb; 79(3-4):445-50. PubMed ID: 10027311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]